Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Karl Keirstead Bullish on GitLab with Buy Rating and Revised Price Target

Elaine Mendonca by Elaine Mendonca
March 5, 2024
in Breaking News
0
Biotechnology Stock Bull Market
0
SHARES
12
VIEWS
Share on FacebookShare on Twitter

Analyst Karl Keirstead from UBS reiterates his bullish stance on GitLab (NASDAQ: GTLB) with a Buy rating, while revising the price target down to $75 from $81. Keirstead remains optimistic about the company’s future prospects and believes in its potential for growth.

GTLB Stock Plummets by 18.67% on March 5, 2024: What Investors Need to Know

On March 5, 2024, GTLB stock experienced a significant drop in price, with shares decreasing by $13.90 since the previous market close. This represents an 18.67% decrease in value, which is a significant decline for investors holding GTLB shares.

The stock opened at $59.95 on March 5, which was $14.52 lower than its previous close. This sharp drop in the opening price indicates that there was likely negative sentiment surrounding GTLB on that day, leading to a sell-off by investors.

Despite this drop in price, GTLB is still trading in the middle of its 52-week range and above its 200-day simple moving average. This suggests that while there was a significant decline on March 5, the stock’s overall performance has been relatively stable compared to its historical range.

GTLB Stock Analysis: Mixed Performances in Revenue, Net Income, and EPS

On March 5, 2024, GTLB stock experienced mixed performances based on the financial data provided by CNN Money. The company reported a total revenue of $579.91 million for the past year, representing a 36.66% increase compared to the previous year. Additionally, the total revenue for the fourth quarter was $163.78 million, showing a 9.43% increase from the previous quarter.

GTLB reported a net income of -$424.17 million for the past year, which is a significant decrease of 146.17% compared to the previous year. On a positive note, the net income for the fourth quarter improved to -$36.47 million, representing an 87.21% increase from the previous quarter.

Earnings per share (EPS) also showed a mixed performance for GTLB stock. The EPS for the past year was -$2.75, indicating a 136.78% decrease compared to the previous year. Interestingly, the EPS for the fourth quarter remained unchanged at -$0.23 compared to the previous quarter.

Overall, the financial data suggests that GTLB stock has experienced both positive and negative performances in various aspects of its financials. Investors may want to closely monitor the company’s future earnings reports and financial updates to assess the stock’s performance and make informed investment decisions.

Tags: GTLB
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ stocks to buy

UBS Analyst Maintains Neutral Rating on Ziff Davis Lowers Price Target to 76

Finance_ projections

Jonathan Painter Sells 23 Million Worth of Kadant Stock

Finance_Assets (2)

SunOpta Receives Buy Rating and Increased Price Target from Analysts

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com